Evidence map›Paper›PMID 41562504›Full record

ArticleClinical pharmacology in drug development2026

A Human Mass Balance and Metabolism Study of [

Ramesh R Boinpally, Joshua Rowe, Pushpa Chandrasekar, Rebecca B White, Eugene E Marcantonio, Nicole Trainor, Yuexia Liang, Cheri Maciolek, James H Small, Robert Houle and 4 more

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology in drug development, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ramesh R BoinpallyClinical Pharmacology, AbbVie Inc., North Chicago, IL, USA.
Joshua RoweLocal Delivery Translational Sciences, AbbVie Inc., Irvine, CA, USA.
Pushpa ChandrasekarLocal Delivery Translational Sciences, AbbVie Inc., Irvine, CA, USA.
Rebecca B WhiteMerck & Co., Inc., West Point, PA, USA.
Eugene E MarcantonioMerck & Co., Inc., Rahway, NJ, USA.
Nicole TrainorMerck & Co., Inc., West Point, PA, USA.
Yuexia LiangMerck & Co., Inc., West Point, PA, USA.
Cheri MaciolekMerck & Co., Inc., West Point, PA, USA.
James H SmallMerck & Co., Inc., West Point, PA, USA.
Robert HouleMerck & Co., Inc., West Point, PA, USA.
Michael J HafeyMerck & Co., Inc., West Point, PA, USA.
Huizhi XieMerck & Co., Inc., West Point, PA, USA.
Jocelyn YabutMerck & Co., Inc., West Point, PA, USA.
Christine FandozziMerck & Co., Inc., West Point, PA, USA.

Funding

AbbVie Inc.Merck & Co., Inc.
6 · The paper itself

Abstract

Ubrogepant is a calcitonin gene-related peptide receptor antagonist approved for the acute treatment of migraine with or without aura in adults. The mass balance and metabolism of ubrogepant was evaluated in six healthy male adults administered a single oral dose of [

Indexed as

Calcitonin Gene-Related Peptide Receptor AntagonistsPyridinesPyrrolesAdministration, OralAdultCarbon RadioisotopesCytochrome P-450 CYP3AFecesHealthy VolunteersHumansMaleMiddle AgedYoung AdultCalcitonin Gene-Related Peptide Receptor AntagonistsCarbon RadioisotopesCytochrome P-450 CYP3APyridinesPyrrolesubrogepantexcretionhuman mass balancemetabolismpharmacokineticsubrogepant

Identifiers

PMID41562504
PMCPMC12821552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.